Clinical trial · Observational
Water Vapor Ablation for Prostate Cancer: Long-Term Registry
Vanquish® Water Vapor Ablation for PrOstate CanceR: Long-Term Registry
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy). This includes longitudinal assessment of patients who have received or will receive the therapy one or multiple times as part of routine clinical care and encompasses those who completed a company-sponsored Vanquish therapy study (as applicable).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Vanquish Therapy | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Vanquish Procedure Patients
- description
- Patients that have completed or will complete a Vanquish therapy and plan to continue their routine clinical care.
- interventionNames
- Device: Vanquish Therapy
Primary outcomes (2)
- measure
- Primary Efficacy Outcome
- timeFrame
- Through study completion, or up to 15 years.
- description
- Freedom from disease specific mortality.
- measure
- Primary Safety Outcome
- timeFrame
- Through study completion, or up to 15 years
- description
- Rate of complications classified as Clavien-Dindo grades III-V and attributable to the Vanquish procedure and/or device over time. * Grade III: Complications requiring surgical intervention (IIIa: laparoscopic, IIIb: open). * Grade IV: Life-threatening complications (IVa: single organ failure, IVb: multi-organ failure). * Grade V: Death of a patient.
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * Candidate for Vanquish therapy per physician discretion or participant has completed a company-sponsored Vanquish therapy study. * Participant is willing and able to provide written informed consent. Exclusion Criteria: * Contraindications per the Vanquish IFU * Previously participated in VAPOR 2 study and is not planning to receive further Vanquish therapy.
References
Publications (0)
Data not yet available